TARGETED THERAPIES Afatinib-new therapy option for EGFR-mutant lung cancer

被引：81

作者：

Yu, Helena A. ^{[1
]}

Pao, William ^{[2
]}

机构：

[1] Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, Dept Med, Thorac Oncol Serv,Div Solid Tumor Oncol, New York, NY 10065 USA

[2] Vanderbilt Ingram Canc Ctr, Div Hematol Oncol, Nashville, TN 37212 USA

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2013年 / 10卷 / 10期

关键词：

1ST-LINE TREATMENT; OPEN-LABEL; ERLOTINIB; CHEMOTHERAPY; MULTICENTER; PHASE-3; TRIAL;

D O I：

10.1038/nrclinonc.2013.154

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

On 15 July 2013, the FDA approved afatinib as a first-line treatment for patients with metastatic non-small-cell lung cancer whose tumours harbour exon 19 deletions or exon 21 (L858R) EGFR substitution mutations. We discuss three recent studies investigating afatinib in this molecular subset of patients.

引用

页码：551 / 552

页数：2

共 50 条

[1] Afatinib—new therapy option for EGFR-mutant lung cancer
Helena A. Yu
William Pao
Nature Reviews Clinical Oncology, 2013, 10 : 551 - 552
[2] Afatinib monotherapy in EGFR-mutant lung adenocarcinoma
Gilbert, Judith A.
LANCET ONCOLOGY, 2013, 14 (09): : E345 - E345
[3] Dacomitinib: another option for EGFR-mutant lung cancer?
Mitsudomi, Tetsuya
LANCET ONCOLOGY, 2014, 15 (13): : 1408 - 1409
[4] Resistance to Afatinib and Cetuximab Combination Therapy in EGFR-mutant Lung Adenocarcinomas
Pirazzoli, Valentina
Takezawa, Ken
de Stanchina, Elisa
Pao, William
Politi, Katerina
CLINICAL CANCER RESEARCH, 2012, 18 (10)
[5] Optimizing the Sequence of Anti-EGFR-Targeted Therapy in EGFR-Mutant Lung Cancer
Meador, Catherine B.
Jin, Hailing
de Stanchina, Elisa
Nebhan, Caroline A.
Pirazzoli, Valentina
Wang, Lu
Lu, Pengcheng
Vuong, Huy
Hutchinson, Katherine E.
Jia, Peilin
Chen, Xi
Eisenberg, Rosana
Ladanyi, Marc
Politi, Katerina
Zhao, Zhongming
Lovly, Christine M.
Cross, Darren A. E.
Pao, William
MOLECULAR CANCER THERAPEUTICS, 2015, 14 (02) : 542 - 552
[6] EGFR-Mutant Lung Cancer: New Drugs
Sequist, Lecia
ONCOLOGIST, 2013, 18 : S1 - S1
[7] New Options for EGFR-Mutant Lung Cancer
不详
CANCER DISCOVERY, 2015, 5 (07) : 687 - 688
[8] Overcoming therapy resistance in EGFR-mutant lung cancer
Antonio Passaro
Pasi A. Jänne
Tony Mok
Solange Peters
Nature Cancer, 2021, 2 : 377 - 391
[9] Overcoming therapy resistance in EGFR-mutant lung cancer
Passaro, Antonio
Janne, Pasi A.
Mok, Tony
Peters, Solange
NATURE CANCER, 2021, 2 (04) : 377 - 391
[10] Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
Zhang, Zhe
Yang, Sen
Wang, Qiming
BIOMARKER RESEARCH, 2019, 7 (01)

← 1 2 3 4 5 →